Deborah Andrews - Lineage Cell Independent Director
| BTX Stock | ILS 447.30 14.00 3.23% |
Director
Ms. Deborah J. Andrews is the Independent Director of BioTime Inc. Ms. Andrews has served as Chief Financial Officer of STAAR Surgical Company since 2017 after serving as Vice President, Chief Accounting Officer since 2013. Ms. Andrews also served as STAAR Surgicals Vice President, Chief Financial Officer from 2005 to 2013, as its Global Controller from 2001 to 2005, and as its Vice President, International Finance from 1999 to 2001. Ms. Andrews previously worked as a senior accountant for a major public accounting firm since 2014.
| Age | 60 |
| Tenure | 10 years |
| Phone | 510-521-3390 |
| Web | http://www.biotimeinc.com |
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Ilan Flato | Tower Semiconductor | 61 | |
| Adrian Percy | Evogene | N/A | |
| Oded Shoseyov | Evogene | 62 | |
| Yocheved Dvir | Nice | 66 | |
| Ziv Kop | Kamada | 43 | |
| Dalia Rabin | Elbit Systems | 66 | |
| Dana Gross | Tower Semiconductor | 51 | |
| Shmuel Rubinstein | Kamada | 78 | |
| Jonathan Hahn | Kamada | 32 | |
| Rina Baum | Elbit Systems | 73 | |
| Yigal Neeman | Elbit Systems | 73 | |
| Rimon BenShaoul | Nice | 74 | |
| Ehood Nisan | Elbit Systems | 51 | |
| Joseph Cowan | Nice | 70 | |
| Alex Kornhauser | Tower Semiconductor | 71 | |
| Kalman Kaufman | Tower Semiconductor | 72 | |
| Sagi Kabla | Tower Semiconductor | 38 | |
| Lea Bloom | Evogene | 42 | |
| Eli Zangvil | Evogene | 45 | |
| Tuvia Shoham | Kamada | 70 | |
| Abraham Havron | Kamada | 71 | |
Lineage Cell Therapeutics Leadership Team
Elected by the shareholders, the Lineage Cell's board of directors comprises two types of representatives: Lineage Cell inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Lineage. The board's role is to monitor Lineage Cell's management team and ensure that shareholders' interests are well served. Lineage Cell's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Lineage Cell's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael Mulroy, Director | ||
| David Schlachet, Independent Director | ||
| Alfred Kingsley, Chairman of the Board | ||
| Judith Segall, Vice President - Administration, Corporate Secretary, Director | ||
| Stephana Patton, General Counsel | ||
| Michael West, Co-CEO, Director | ||
| Deborah Andrews, Independent Director | ||
| Chase Leavitt, General Counsel and Corporate Secretary | ||
| Matt Haines, IR Contact Officer | ||
| Don Bailey, Director | ||
| David Nakasone, Director - Investor Relations | ||
| Russell Skibsted, CFO | ||
| Brian Culley, President CEO, Director | ||
| Brandi Roberts, CFO, Senior Vice President - Finance | ||
| Pedro Lichtinger, President CEO of Asterias Biotherapeutics | ||
| Neal Bradsher, Independent Director | ||
| Angus Russell, Director | ||
| Aditya Mohanty, Co-President Co-CEO, Director | ||
| Cavan Redmond, Independent Director | ||
| Stephen Farrell, Independent Director |
Lineage Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Lineage Cell a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Price To Book | 1.14 X | |||
| Price To Sales | 39.20 X | |||
| Revenue | 4.99 M | |||
| Gross Profit | 4.69 M | |||
| EBITDA | (37.2 M) | |||
| Net Income | (45.99 M) | |||
| Cash And Equivalents | 27.1 M | |||
| Cash Per Share | 0.18 X | |||
| Total Debt | 5.09 M | |||
| Debt To Equity | 3.10 % |
Pair Trading with Lineage Cell
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lineage Cell position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lineage Cell will appreciate offsetting losses from the drop in the long position's value.Moving against Lineage Stock
| 0.7 | PLTF | Value Capital One | PairCorr |
| 0.63 | EDRL | Edri El | PairCorr |
| 0.49 | BLRX | BioLine RX | PairCorr |
The ability to find closely correlated positions to Lineage Cell could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lineage Cell when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lineage Cell - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lineage Cell Therapeutics to buy it.
The correlation of Lineage Cell is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lineage Cell moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lineage Cell Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Lineage Cell can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Lineage Cell Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Complementary Tools for Lineage Stock analysis
When running Lineage Cell's price analysis, check to measure Lineage Cell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lineage Cell is operating at the current time. Most of Lineage Cell's value examination focuses on studying past and present price action to predict the probability of Lineage Cell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lineage Cell's price. Additionally, you may evaluate how the addition of Lineage Cell to your portfolios can decrease your overall portfolio volatility.
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |